Murray D. Krahn, MD, MSc
University of Toronto and University Health Network, Toronto General Research Institute, Toronto Health Economics and Technology Assessment (THETA) Collaborative
Faculty of Pharmacy
200 Elizabeth Street
10th floor
Toronto,
ON
Canada
M5G 2C4
Papers:
1C-6
INVESTIGATING STRUCTURAL INDEPENDENCE IN PREFERENCE-BASED UTILITY INSTRUMENTS USING GRAPHICAL MODELS
5O-1
VALIDATING THE BLADDER UTILITY SYMPTOM SCALE (BUSS): A MULTIATTRIBUTE HEALTH STATE CLASSIFICATION SYSTEM FOR ALL PATIENTS WITH BLADDER CANCER
PANEL: RECOMMENDATIONS OF THE SECOND PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE
COST-EFFECTIVENESS ANALYSIS OF DRUGS FOR CHRONIC HEPATITIS C INFECTION: INFORMING ON LISTING DECISIONS OF INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS IN CANADA
CORNEAL CROSS-LINKING VERSUS PENETRATING KERATOPLASTY IN THE TREATMENT OF KERATOCONUS: A COST-EFFECTIVENESS ANALYSIS
PREFERENCES OF PREGNANT WOMEN AND FAMILY MEMBERS FOR COMBINED MATERNAL-FETAL HEALTH STATES ARISING FROM THE USE OF ANTICOAGULATION IN PREGNANCY
WEIGHTING OF AHI SCORES AND SYMPTOMS IN THE DIAGNOSIS OF SLEEP APNEA BY SLEEP SPECIALISTS
A SYSTEMATIC REVIEW AND META-ANALYSIS OF HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS
HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS WITH LATE-STAGE LIVER DISEASE
CHALLENGES ON THE PATH TO REIMBURSEMENT OF ONCOLOGY DRUGS: INSIGHTS FROM THE COST-EFFECTIVENESS DECISIONS OF THE PAN-CANADIAN ONCOLOGY DRUG REVIEW